Article info
PDFTherapeutics
Randomised Controlled Trial
Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance
- Correspondence to Professor Philip Home
ICM-Diabetes, The Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK; philip.home{at}ncl.ac.uk
Citation
Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance
Publication history
- First published November 16, 2010.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions